Financiado en parte por DSM, DSM Nutritional Products
Higher dose docosahexaenoic acid supplementation during pregnancy and early preterm birth: A randomised, double-blind, adaptive-design superiority trial
Carlson SE, Gajewski BJ, Valentine CJ, Kerling EH, Weiner CP, Cackovic M, Buhimschi CS, Rogers LK, Sands SA, Brown AR, Mudaranthakam DP, Crawford SA, DeFranco EA
EClinicalMedicine · 73 citas
Etiquetas de revisión
Financiado por la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiado por la industria
- Universidad u hospital
- University of Cincinnati
- Gobierno
- Diagnostic Services Manitoba
- Empresa
- DSM
- Gobierno
- National Institutes of Health
- Empresa
- DSM Nutritional Products
- Gobierno
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Gobierno
- NICHD NIH HHS
- Subvenciones
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01 HD083292); Diagnostic Services Manitoba (R01HD083292); DSM (2646554); DSM (15/991,735)
Según 7 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2021-05-17 · EClinicalMedicine · vol. 36 · pág. 100905
- Editorial
- Elsevier BV
- Citado
- 96 citas · más que el 98% de estudios similares · 7.0× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 36 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Fatty Acid Research and Health · Infant Nutrition and Health · Neonatal Respiratory Health Research
- Palabras clave
- Medicine, Docosahexaenoic acid, Pregnancy, Gestation, Randomization, Randomized controlled trial, Obstetrics, Live birth, Clinical endpoint, Gestational age, Pediatrics, Internal medicine, Fatty acid, Polyunsaturated fatty acid
13 autores
- Susan E. Carlson🇺🇸 · autor de correspondenciaUniversity of Kansas Medical Center
- Byron J. Gajewski🇺🇸University of Kansas Medical Center
- Christina Jensen Valentine🇺🇸University of Cincinnati
- Elizabeth H. Kerling🇺🇸University of Kansas Medical Center
- Carl P. Weiner🇺🇸University of Kansas Medical Center
- Michael Cackovic🇺🇸The Ohio State University
- Catalin Sorin Buhimschi🇺🇸University of Illinois Chicago
- Lynette Kay Rogers🇺🇸Nationwide Children's Hospital
- Scott A. Sands🇺🇸University of Kansas Medical Center
- Alexandra R. Brown🇺🇸University of Kansas Medical Center
- Dinesh Pal Mudaranthakam🇺🇸University of Kansas Medical Center
- Sarah Adelaide Crawford🇺🇸University of Kansas Medical Center
- Emily A. DeFranco🇺🇸University of Cincinnati
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Several meta analyses have concluded n-3 fatty acids, including docosahexaenoic acid (DHA), reduce early preterm birth (EPB, < 34 weeks), however, the amount of DHA required is unclear. We hypothesized that 1000 mg DHA per day would be superior to 200 mg, the amount in most prenatal supplements.
Methods
This randomised, multicentre, double-blind, adaptive-design, superiority trial was conducted in three USA medical centres. Women with singleton pregnancies and 12 to 20 weeks gestation were eligible. randomization was generated in SAS® by site in blocks of 4. The planned adaptive design periodically generated allocation ratios favoring the better performing dose. Managing study personnel were blind to treatment until 30 days after the last birth. The primary outcome was EPB by dose and by enrolment DHA status (low/high). Bayesian posterior probabilities (pp) were determined for planned efficacy and safety outcomes using intention-to-treat. The study is registered with ClinicalTrials.gov (NCT02626299) and closed to enrolment.
Findings
Eleven hundred participants (1000 mg, n = 576; 200 mg, n = 524) were enrolled between June 8, 2016 and March 13, 2020 with the last birth September 5, 2020. 1032 (n = 540 and n = 492) were included in the primary analyses. The higher dose had a lower EPB rate [1.7% (9/540) vs 2.4% (12/492), pp=0.81] especially if participants had low DHA status at enrolment [2.0% (5/249) vs 4.1%, (9/219), pp=0.93]. Participants with high enrolment DHA status did not realize a dose effect [1000 mg: 1.4% (4/289); 200 mg: 1.1% (3/271), pp = 0.57]. The higher dose was associated with fewer serious adverse events (maternal: chorioamnionitis, premature rupture of membranes and pyelonephritis; neonatal: feeding, genitourinary and neurologic problems, all pp>0.90).
Interpretation
Clinicians could consider prescribing 1000 mg DHA daily during pregnancy to reduce EPB in women with low DHA status if they are able to screen for DHA.
Funding
The National Institutes of Health Child Health and Human Development (NICHD) funded the study. Life's DHA™-S oil, DSM Nutritional Products LLC, Switzerland provided all capsules.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.